Clinical Trial Update: Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of venetoclax, ixazomib citrate (MLN9708), and dexamethasone for relapsed or refractory AL amyloidosis. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• NINLARO (ixazomib)
• Venclyxto (Venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 | Status: RECRUITING